Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kim M. Knudsen"'
Autor:
Kim M. Knudsen, Thomas R. Pieber, Julie Willard, Benedikte Bandak, Ulrike Hövelmann, Ramin Tehranchi, Leona Plum-Mörschel, Ronnie Aronson
Publikováno v:
Diabetes Care
OBJECTIVE To evaluate the efficacy and safety of dasiglucagon, a ready-to-use, next-generation glucagon analog in aqueous formulation for subcutaneous dosing, for treatment of severe hypoglycemia in adults with type 1 diabetes. RESEARCH DESIGN AND ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3218a52a5a65444c39c3f05875a3c86
http://europepmc.org/articles/PMC8247529
http://europepmc.org/articles/PMC8247529
Autor:
MINNA B. OLSEN, ULRIKE HÖVELMANN, JON GRIFFIN, KIM M. KNUDSEN, PER-OLOF ERIKSSON, MIKKEL A. AGERSNAP
Publikováno v:
Diabetes. 71
Dapiglutide is a first-in-class peptide with dual activity on the GLP-1 and GLP-2 receptors and with potential to treat several metabolic/gastrointestinal (GI) diseases. In a multiple ascending dose cohort trial, 40 healthy subjects (mean BMI 24.6 kg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c46bda5cf93a8951df83bda5423262dc
https://doi.org/10.2337/db22-335-or
https://doi.org/10.2337/db22-335-or
Autor:
Elmieke P. J. Boot, Frank J. Beurskens, Kim M. Knudsen, Ole Baadsgaard, Jessica L. Teeling, Claus Zachariae, Paul W. H. I. Parren, Debra Hudson, David Satijn, Jan G. J. van de Winkel, Sakari Reitamo, Lone Skov
Publikováno v:
The Journal of Immunology. 181:669-679
IL-8 is a chemokine that has been implicated in a number of inflammatory diseases involving neutrophil activation. HuMab 10F8 is a novel fully human mAb against IL-8, which binds a discontinuous epitope on IL-8 overlapping the receptor binding site,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eb317338bdbe11e394e7345b037144f
https://doi.org/10.4049/jimmunol.181.1.669
https://doi.org/10.4049/jimmunol.181.1.669
Autor:
Roland Kaufmann, Anders Österborg, Madeleine Duvic, Youn H. Kim, Steen Lisby, Susan J. Knox, Robert Gniadecki, Erik Obitz, Timothy M Illidge, Kim M. Knudsen, Ole Baadsgaard, Lars Iversen, Sean Whittaker, Thomas Schwarz, Kevin D. Cooper
Publikováno v:
Kim, Y H, Duvic, M, Obitz, E, Gniadecki, R, Iversen, L, Osterborg, A, Whittaker, S, Illidge, T M, Kaufmann, R, Cooper, K, Knudsen, K M, Lisby, S, Baadsgaard, O & Schwartz, T 2007, ' Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. ', Blood, vol. 109, no. 11, pp. 4655-62 . https://doi.org/10.1182/blood-2006-12-062877
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, uncontrolled clinical studies. Patients with treatment refractory CD4+ CTCL (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28680038a516b69e71ddf68b71d2a136
https://pubmed.ncbi.nlm.nih.gov/17311990
https://pubmed.ncbi.nlm.nih.gov/17311990